Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation

Human Molecular Genetics

Volumn 19, Issue 16, 2010, Pages 3190-3205

  Chaturvedi, Rajnish K ^a,b   Calingasan, Noel Y ^a   Yang, Lichuan ^a   Hennessey, Thomas ^a   Johri, Ashu ^a   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; ESTROGEN RELATED RECEPTOR ALPHA; GUANIDINOPROPIONIC ACID; HUNTINGTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF1; TRANSCRIPTION FACTOR NRF2; UNCOUPLING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; BROWN ADIPOSE TISSUE; CELL DEGENERATION; CELL VACUOLE; CONTROLLED STUDY; CORPUS STRIATUM; ENERGY BALANCE; ENERGY DEPRIVATION; EXPERIMENTAL MODEL; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION; GLIOSIS; GLUCONEOGENESIS; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; LIPID STORAGE; LIVER CELL; LIVER LEVEL; MALE; MOUSE; NEUROPATHOLOGY; NEUROPIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; THERMOREGULATION; TRANSGENIC MOUSE; WILD TYPE;

ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOTTING, WESTERN; CEREBRAL CORTEX; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DNA, MITOCHONDRIAL; ENERGY METABOLISM; FATTY LIVER; GENE EXPRESSION; GUANIDINES; HUMANS; HUNTINGTON DISEASE; IMMUNOHISTOCHEMISTRY; ION CHANNELS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIAL PROTEINS; NUCLEAR RESPIRATORY FACTOR 1; PERIPHERAL NERVOUS SYSTEM DISEASES; PROPIONIC ACIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS;

MUS; MUS MUSCULUS;

EID: 77955017449     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq229     Document Type: Article

References (85)

1. Pratley, R.E., Salbe, A.D., Ravussin, E. and Caviness, J.N. (2000) Higher sedentary energy expenditure in patients with Huntington's disease. Ann. Neurol., 47, 64-70.
2. Goodman, A.O., Murgatroyd, P.R., Medina-Gomez, G., Wood, N.I., Finer, N., Vidal-Puig, A.J., Morton, A.J. and Barker, R.A. (2008) The metabolic profile of early Huntington's disease-a combined human and transgenic mouse study. Exp. Neurol., 210, 691-698.
3. Djousse, L., Knowlton, B., Cupples, L.A., Marder, K., Shoulson, I. and Myers, R.H. (2002) Weight loss in early stage of Huntington's disease. Neurology, 59, 1325-1330.
4. Sathasivam, K., Hobbs, C., Turmaine, M., Mangiarini, L., Mahal, A., Bertaux, F., Wanker, E.E., Doherty, P., Davies, S.W. and Bates, G.P. (1999) Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet., 8, 813-822.
5. Ribchester, R.R., Thomson, D., Wood, N.I., Hinks, T., Gillingwater, T.H., Wishart, T.M., Court, F.A. and Morton, A.J. (2004) Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur. J. Neurosci., 20, 3092-3114.
6. Grafton, S.T., Mazziotta, J.C., Pahl, J.J., St George-Hyslop, P., Haines, J.L., Gusella, J., Hoffman, J.M., Baxter, L.R. and Phelps, M.E. (1992) Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch. Neurol., 49, 1161-1167.
7. Feigin, A., Leenders, K.L., Moeller, J.R., Missimer, J., Kuenig, G., Spetsieris, P., Antonini, A. and Eidelberg, D. (2001) Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J. Nucl. Med., 42, 1591-1595.
8. Antonini, A., Leenders, K.L., Spiegel, R., Meier, D., Vontobel, P., Weigell-Weber, M., Sanchez-Pernaute, R., de Yebenez, J.G., Boesiger, P., Weindl, A. et al. (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain, 119, 2085-2095.
9. Kuwert, T., Lange, H.W., Boecker, H., Titz, H., Herzog, H., Aulich, A., Wang, B.C., Nayak, U. and Feinendegen, L.E. (1993) Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease. J. Neurol., 241, 31-36.
10. Jenkins, B.G., Koroshetz, W.J., Beal, M.F. and Rosen, B.R. (1993) Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology, 43, 2689-2695.
11. Koroshetz, W.J., Jenkins, B.G., Rosen, B.R. and Beal, M.F. (1997) Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol., 41, 160-165.
12. Lodi, R., Schapira, A.H., Manners, D., Styles, P., Wood, N.W., Taylor, D.J. and Warner, T.T. (2000) Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol., 48, 72-76.
13. Saft, C., Zange, J., Andrich, J., Muller, K., Lindenberg, K., Landwehrmeyer, B., Vorgerd, M., Kraus, P.H., Przuntek, H. and Schols, L. (2005) Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov. Disord., 20, 674-679.
14. Browne, S.E., Bowling, A.C., MacGarvey, U., Baik, M.J., Berger, S.C., Muqit, M.M., Bird, E.D. and Beal, M.F. (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol., 41, 646-653.
15. Gu, M., Gash, M.T., Mann, V.M., Javoy-Agid, F., Cooper, J.M. and Schapira, A.H. (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol., 39, 385-389.
16. Tabrizi, S.J., Cleeter, M.W., Xuereb, J., Taanman, J.W., Cooper, J.M. and Schapira, A.H. (1999) Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol., 45, 25-32.
17. Seong, I.S., Ivanova, E., Lee, J.M., Choo, Y.S., Fossale, E., Anderson, M., Gusella, J.F., Laramie, J.M., Myers, R.H., Lesort, M. et al. (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet., 14, 2871-2880.
18. Milakovic, T. and Johnson, G.V. (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J. Biol. Chem., 280, 30773-30782.
19. Beal, M.F., Brouillet, E., Jenkins, B., Henshaw, R., Rosen, B. and Hyman, B.T. (1993) Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem., 61, 1147-1150.
20. Brouillet, E., Hantraye, P., Ferrante, R.J., Dolan, R., Leroy-Willig, A., Kowall, N.W. and Beal, M.F. (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl Acad. Sci. USA, 92, 7105-7109.
21. Ludolph, A.C., He, F., Spencer, P.S., Hammerstad, J. and Sabri, M. (1991) 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J. Neurol. Sci., 18, 492-498.
22. Brouillet, E., Jenkins, B.G., Hyman, B.T., Ferrante, R.J., Kowall, N.W., Srivastava, R., Roy, D.S., Rosen, B.R. and Beal, M.F. (1993) Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem., 60, 356-359.
23. Orr, A.L., Li, S., Wang, C.E., Li, H., Wang, J., Rong, J., Xu, X., Mastroberardino, P.G., Greenamyre, J.T. and Li, X.J. (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci., 28, 2783-2792.
24. Reddy, P.H., Mao, P. and Manczak, M. (2009) Mitochondrial structural and functional dynamics in Huntington's disease. Brain. Res. Rev., 61, 33-48.
25. Choo, Y.S., Johnson, G.V., MacDonald, M., Detloff, P.J. and Lesort, M. (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet., 13, 1407-1420.
26. Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R., Strittmatter, W.J. and Greenamyre, J.T. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci., 5, 731-736.
27. Rockabrand, E., Slepko, N., Pantalone, A., Nukala, V.N., Kazantsev, A., Marsh, J.L., Sullivan, P.G., Steffan, J.S., Sensi, S.L. and Thompson, L.M. (2007) The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum. Mol. Genet., 16, 61-77.
28. Cha, J.H. (2007) Transcriptional signatures in Huntington's disease. Prog. Neurobiol., 83, 228-248.
29. Sugars, K.L. and Rubinsztein, D.C. (2003) Transcriptional abnormalities in Huntington disease. Trends Genet., 19, 233-238.
30. Dunah, A.W., Jeong, H., Griffin, A., Kim, Y.M., Standaert, D.G., Hersch, S.M., Mouradian, M.M., Young, A.B., Tanese, N. and Krainc, D. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science, 296, 2238-2243.
31. Nucifora, F.C. Jr, Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L. et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science, 291, 2423-2428.
32. Steffan, J.S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.Z., Gohler, H., Wanker, E.E., Bates, G.P., Housman, D.E. and Thompson, L.M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 97, 6763-6768.
33. Leone, T.C., Lehman, J.J., Finck, B.N., Schaeffer, P.J., Wende, A.R., Boudina, S., Courtois, M., Wozniak, D.F., Sambandam, N., Bernal-Mizrachi, C. et al. (2005) PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS. Biol., 3, e101.
34. Lin, J., Wu, P.H., Tarr, P.T., Lindenberg, K.S., St-Pierre, J., Zhang, C.Y., Mootha, V.K., Jager, S., Vianna, C.R., Reznick, R.M. et al. (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell, 119, 121-135.
35. Puigserver, P. and Spiegelman, B.M. (2003) Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev., 24, 78-90.
36. Puigserver, P., Wu, Z., Park, C.W., Graves, R., Wright, M. and Spiegelman, B.M. (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell, 92, 829-839.
37. Lin, J., Handschin, C. and Spiegelman, B.M. (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell. Metab., 1, 361-370.
38. Kelly, D.P. and Scarpulla, R.C. (2004) Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev., 18, 357-368.
39. Wareski, P., Vaarmann, A., Choubey, V., Safiulina, D., Liiv, J., Kuum, M. and Kaasik, A. (2009) PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J. Biol. Chem., 284, 21379-21385.
40. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P. et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 127, 1109-1122.
41. Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K. et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444, 337-342.
42. Pearson, K.J., Baur, J.A., Lewis, K.N., Peshkin, L., Price, N.L., Labinskyy, N., Swindell, W.R., Kamara, D., Minor, R.K., Perez, E. et al. (2008) Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab., 8, 157-168.
43. Cui, L., Jeong, H., Borovecki, F., Parkhurst, C.N., Tanese, N. and Krainc, D. (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 127, 59-69.
44. Weydt, P., Pineda, V.V., Torrence, A.E., Libby, R.T., Satterfield, T.F., Lazarowski, E.R., Gilbert, M.L., Morton, G.J., Bammler, T.K., Strand, A.D. et al. (2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab., 4, 349-362.
45. Chaturvedi, R.K., Adhihetty, P., Shukla, S., Hennessy, T., Calingasan, N., Yang, L., Starkov, A., Kiaei, M., Cannella, M., Sassone, J. et al. (2009) Impaired PGC-1alpha function in muscle in Huntington's disease. Hum. Mol. Genet., 18, 3048-3065.
46. Phan, J., Hickey, M.A., Zhang, P., Chesselet, M.F. and Reue, K. (2009) Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum. Mol. Genet., 18, 1006-1016.
47. Okamoto, S., Pouladi, M.A., Talantova, M., Yao, D., Xia, P., Ehrnhoefer, D.E., Zaidi, R., Clemente, A., Kaul, M., Graham, R.K. et al. (2009) Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med., 15, 1407-1413.
48. Lee, S.T., Chu, K., Jung, K.H., Im, W.S., Park, J.E., Lim, H.C., Won, C.H., Shin, S.H., Lee, S.K., Kim, M. et al. (2009) Slowed progression in models of Huntington disease by adipose stem cell transplantation. Ann. Neurol., 66, 671-681.
49. Zong, H., Ren, J.M., Young, L.H., Pypaert, M., Mu, J., Birnbaum, M.J. and Shulman, G.I. (2002) AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl Acad. Sci. USA, 99, 15983-15987.
50. Reznick, R.M., Zong, H., Li, J., Morino, K., Moore, I.K., Yu, H.J., Liu, Z.X., Dong, J., Mustard, K.J., Hawley, S.A. et al. (2007) Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab., 5, 151-156.
51. Williams, D.B., Sutherland, L.N., Bomhof, M.R., Basaraba, S.A., Thrush, A.B., Dyck, D.J., Field, C.J. and Wright, D.C. (2009) Muscle-specific differences in the response of mitochondrial proteins to beta-GPA feeding: an evaluation of potential mechanisms. Am. J. Physiol. Endocrinol. Metab., 296, E1400-E1408.
52. Jager, S., Handschin, C., St-Pierre, J. and Spiegelman, B.M. (2007) AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl Acad. Sci. USA, 104, 12017-12022.
53. Schilling, G., Savonenko, A.V., Klevytska, A., Morton, J.L., Tucker, S.M., Poirier, M., Gale, A., Chan, N., Gonzales, V., Slunt, H.H. et al. (2004) Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice. Hum. Mol. Genet., 13, 1599-1610.
54. Fitch, C.D., Jellinek, M. and Mueller, E.J. (1974) Experimental depletion of creatine and phosphocreatine from skeletal muscle. J. Biol. Chem., 249, 1060-1063.
55. Shoubridge, E.A., Challiss, R.A., Hayes, D.J. and Radda, G.K. (1985) Biochemical adaptation in the skeletal muscle of rats depleted of creatine with the substrate analogue beta-guanidinopropionic acid. Biochem. J., 232, 125-131.
56. Luthi-Carter, R., Hanson, S.A., Strand, A.D., Bergstrom, D.A., Chun, W., Peters, N.L., Woods, A.M., Chan, E.Y., Kooperberg, C., Krainc, D. et al. (2002) Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet., 11, 1911-1926.
57. D'Aurelio, M., Vives-Bauza, C., Davidson, M.M. and Manfredi, G. (2010) Mitochondrial DNA background modifies the bioenergetics of NARP/MILS ATP6 mutant cells. Hum. Mol. Genet., 19, 374-386.
58. St-Pierre, J., Lin, J., Krauss, S., Tarr, P.T., Yang, R., Newgard, C.B. and Spiegelman, B.M. (2003) Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J. Biol. Chem., 278, 26597-26603.
59. Browne, S.E. and Beal, M.F. (2006) Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox Signal., 8, 2061-2073.
60. Hersch, S.M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L. et al. (2006) Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 66, 250-252.
61. Kosinski, C.M., Schlangen, C., Gellerich, F.N., Gizatullina, Z., Deschauer, M., Schiefer, J., Young, A.B., Landwehrmeyer, G.B., Toyka, K.V., Sellhaus, B. et al. (2007) Myopathy as a first symptom of Huntington's disease in a Marathon runner. Mov. Disord., 22, 1637-1640.
62. Turner, C., Cooper, J.M. and Schapira, A.H. (2007) Clinical correlates of mitochondrial function in Huntington's disease muscle. Mov. Disord., 22, 1715-1721.
63. Gizatullina, Z.Z., Lindenberg, K.S., Harjes, P., Chen, Y., Kosinski, C.M., Landwehrmeyer, B.G., Ludolph, A.C., Striggow, F., Zierz, S. and Gellerich, F.N. (2006) Low stability of Huntington muscle mitochondria against Ca2+ in R6/2 mice. Ann. Neurol., 59, 407-411.
64. Mihm, M.J., Amann, D.M., Schanbacher, B.L., Altschuld, R.A., Bauer, J.A. and Hoyt, K.R. (2007) Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis., 25, 297-308.
65. Lin, J., Wu, H., Tarr, P.T., Zhang, C.Y., Wu, Z., Boss, O., Michael, L.F., Puigserver, P., Isotani, E., Olson, E.N. et al. (2002) Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature, 418, 797-801.
66. Benn, C.L., Sun, T., Sadri-Vakili, G., McFarland, K.N., DiRocco, D.P., Yohrling, G.J., Clark, T.W., Bouzou, B. and Cha, J.H. (2008) Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J. Neurosci., 28, 10720-10733.
67. Giampa, C., Middei, S., Patassini, S., Borreca, A., Marullo, F., Laurenti, D., Bernardi, G., Ammassari-Teule, M. and Fusco, F.R. (2009) Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. Eur. J. Neurosci., 29, 902-910.
68. DeMarch, Z., Giampa, C., Patassini, S., Bernardi, G. and Fusco, F.R. (2008) Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis., 30, 375-387.
69. Jiang, H., Nucifora, F.C. Jr, Ross, C.A. and DeFranco, D.B. (2003) Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum. Mol. Genet., 12, 1-12.
70. Jiang, H., Poirier, M.A., Liang, Y., Pei, Z., Weiskittel, C.E., Smith, W.W., DeFranco, D.B. and Ross, C.A. (2006) Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol. Dis., 23, 543-551.
71. St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J.M., Rhee, J., Jager, S., Handschin, C., Zheng, K., Lin, J., Yang, W. et al. (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell, 127, 397-408.
72. Herzig, S., Long, F., Jhala, U.S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schutz, G., Yoon, C., Puigserver, P. et al. (2001) CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature, 413, 179-183.
73. Hinerfeld, D., Traini, M.D., Weinberger, R.P., Cochran, B., Doctrow, S.R., Harry, J. and Melov, S. (2004) Endogenous mitochondrial oxidative stress: neurodegeneration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice. J. Neurochem., 88, 657-667.
74. Estall, J.L., Kahn, M., Cooper, M.P., Fisher, F.M., Wu, M.K., Laznik, D., Qu, L., Cohen, D.E., Shulman, G.I. and Spiegelman, B.M. (2009) Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression. Diabetes, 58, 1499-1508.
75. Weydt, P., Soyal, S.M., Gellera, C., Didonato, S., Weidinger, C., Oberkofler, H., Landwehrmeyer, G.B. and Patsch, W. (2009) The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease. Mol. Neurodegener., 4,3.
76. Taherzadeh-Fard, E., Saft, C., Andrich, J., Wieczorek, S. and Arning, L. (2009) PGC-1alpha as modifier of onset age in Huntington disease. Mol. Neurodegener., 4, 10.
77. Kelly, T.J., Lerin, C., Haas, W., Gygi, S.P. and Puigserver, P. (2009) GCN5-mediated transcriptional control of the metabolic coactivator PGC-1beta through lysine acetylation. J. Biol. Chem., 284, 19945-19952.
78. Canto, C. and Auwerx, J. (2009) PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol., 20, 98-105.
79. Dominy, J.E. Jr, Lee, Y., Gerhart-Hines, Z. and Puigserver, P. (2009) Nutrient-dependent regulation of PGC-1alpha's acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5. Biochim. Biophys. Acta. In press.
80. Quintanilla, R.A., Jin, Y.N., Fuenzalida, K., Bronfman, M. and Johnson, G.V. (2008) Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J. Biol. Chem., 283, 25628-25637.
81. Wenz, T., Diaz, F., Spiegelman, B.M. and Moraes, C.T. (2008) Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab., 8, 249-256.
82. Ma, T.C., Buescher, J.L., Oatis, B., Funk, J.A., Nash, A.J., Carrier, R.L. and Hoyt, K.R. (2007) Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci. Lett., 411, 98-103.
83. Miura, S., Tomitsuka, E., Kamei, Y., Yamazaki, T., Kai, Y., Tamura, M., Kita, K., Nishino, I. and Ezaki, O. (2006) Overexpression of peroxisome proliferator-activated receptor gamma co-activator-1alpha leads to muscle atrophy with depletion of ATP. Am. J. Pathol., 169, 1129-1139.
84. Lehman, J.J., Barger, P.M., Kovacs, A., Saffitz, J.E., Medeiros, D.M. and Kelly, D.P. (2000) Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J. Clin. Invest., 106, 847-856.
85. Liang, H., Balas, B., Tantiwong, P., Dube, J., Goodpaster, B.H., O'Doherty, R.M., DeFronzo, R.A., Richardson, A., Musi, N. and Ward, W.F. (2009) Whole body overexpression of PGC-1alpha has opposite effects on hepatic and muscle insulin sensitivity. Am. J. Physiol. Endocrinol. Metab., 296, E945-E954.